Missouri is currently home to 1899 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome
NCT05944562
Recruiting
The hypotheses of this study are that single agent CPI-0209 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patients, CPI-0209 will demonstrate efficacy and be worth of further study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Mycosis Fungoides, Sezary Syndrome, Mycosis Fungoides/Sezary Syndrome
Register for Updates
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
NCT06828055
Recruiting
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once daily.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Viking Clinical Site #112, Kansas City, Missouri
Conditions: Weight Loss
Register for Updates
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
NCT05844982
Recruiting
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Retina Research Institute, LLC, Saint Louis, Missouri
Conditions: Radiation Retinopathy, Visual Impairment
Register for Updates
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT05659381
Recruiting
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 3-4 cycles). Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: University of Kansas Cancer Center, Kansas City, Missouri
Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
Register for Updates
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
NCT05347771
Recruiting
This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/18/2025
Locations: Washington University at St. Louis, Saint Louis, Missouri
Conditions: Asthma
Register for Updates
Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)
NCT05268094
Recruiting
COMPASS is a prospective multicenter randomized interventional trial. Participants with ductal-dependent pulmonary blood flow will be randomized to receive either a systemic-to-pulmonary artery shunt or ductal artery stent. Block randomization will be performed by center and by single vs. two ventricle status. Participants will be followed through the first year of life.
Gender:
ALL
Ages:
Between 1 day and 30 days
Trial Updated:
02/18/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Congenital Heart Disease in Children
Register for Updates
Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes
NCT06503809
Recruiting
Despite strong evidence that tight control of blood sugar reduces the risk of diabetes complications, most people with type 1 diabetes do not achieve recommended blood sugar targets. This randomized controlled trial will test whether a very-low- carbohydrate ketogenic diet can effectively and safely improve blood sugar control in adults with type 1 diabetes.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/17/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
NCT05471908
Recruiting
Compare the effectiveness of automatic vs as-needed (PRN) post-hospitalization follow-up for children who are hospitalized for common infections.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
02/17/2025
Locations: St. Louis Children's Hospital, Saint Louis, Missouri
Conditions: Pneumonia, Urinary Tract Infections, Soft Tissue Infections, Gastroenteritis
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682
Recruiting
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Saint Francis Medical Center, Cape Girardeau, Missouri
Conditions: Lung Non-Small Cell Carcinoma
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688
Recruiting
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: Saint Francis Medical Center, Cape Girardeau, Missouri
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation
NCT06812429
Recruiting
The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: Inflammation
Register for Updates
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
NCT04318717
Recruiting
This is an open-label, single center, one cohort, non-randomized, phase II study. The aim is to evaluate the efficacy and safety of the combination of hypofractionated radiotherapy (HRT) and pembrolizumab on local tumor control in mucosal melanoma patients. Treatment effect will be compared with historical radiation therapy-alone control data.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
02/13/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Mucosal Melanoma of the Head and Neck
Register for Updates